0002008861false00020088612025-06-252025-06-25

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_______________________________
FORM 8-K
_______________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): June 25, 2025
_____________________________
Endo, Inc.
(Exact name of registrant as specified in its charter)
_______________________________
Delaware
333-280767
30-1390281
(State or other jurisdiction
of incorporation)
(Commission File Number)
(IRS Employer
Identification No.)
9 Great Valley Parkway
Malvern,
Pennsylvania
19355
(Address of principal executive offices)
(Zip Code)
Registrant's telephone number, including area code 484-216-0000
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act: None (1)
(1)
On June 28, 2024, Endo, Inc. common stock was quoted and began trading on the OTCQX® Best Market under the symbol “NDOI.”
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



Item 5.07. Submission of Matters to a Vote of Security Holders.
On June 25, 2025, Endo, Inc. (the Company) held its 2025 Annual Meeting of Shareholders (the Annual Meeting) in Malvern, Pennsylvania. The matters voted on by shareholders at the Annual Meeting and the results of such voting are set forth below.
1.The proposal to elect, by separate resolutions, the following directors, representing all of the members of the Board of Directors of the Company (the Board), to serve until the next annual meeting of stockholders or until their death, resignation or removal, if earlier, was approved based upon the following votes:
NomineeVotes For ApprovalVotes AgainstAbstentionsBroker Non-Votes
Paul Efron54,024,364 256,309 10,002 16,054,006 
Paul Herendeen54,258,658 22,015 10,002 16,054,006 
Scott Hirsch54,289,928 745 16,054,006 
Sophia Langlois54,275,482 5,191 10,002 16,054,006 
Andy Pasternak54,235,325 45,348 10,002 16,054,006 
Marc Yoskowitz54,235,325 45,348 10,002 16,054,006 
2.The proposal to approve, on an advisory basis, the compensation of the Company's named executive officers received the following votes:
Votes for approval54,275,482 
Votes against15,191 
Abstentions
Broker non-votes16,054,006 
3.The proposal to approve, by advisory vote, the frequency of future advisory votes on named executive officer compensation received the following votes:
For one year54,278,616 
For two years60 
For three years11,997 
Abstentions
Broker non-votes16,054,006 
Based on these results and good corporate governance, the Board has determined to hold an advisory vote to approve the compensation of the Company’s named executive officers every year until the next required advisory vote on the frequency of future advisory votes to approve the compensation of the Company’s named executive officers or until the Board otherwise determines that a different frequency for such advisory votes is in the best interests of the stockholders of the Company.
4.The proposal to approve the selection of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the year ending December 31, 2025 and to authorize the Board, acting through the Audit & Finance Committee, to determine the independent registered public accounting firm's remuneration was approved based upon the following votes:
Votes for approval70,338,933 
Votes against5,746 
Abstentions
5.Such other matters as may properly come before the Annual Meeting or any adjournment or postponement thereof:
None.




Item 9.01. Financial Statements and Exhibits.
(d)    Exhibits.
NumberDescription
104Cover Page Interactive Data File (embedded within the Inline XBRL document)





SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
ENDO, INC.
By:/s/ Matthew J. Maletta
Name:Matthew J. Maletta
Title:Executive Vice President,
Chief Legal Officer and Secretary
Dated: June 25, 2025